Patents Represented by Attorney, Agent or Law Firm James F. Halsey, Jr.
  • Inhibitors of interleukin-1&bgr; converting enzyme
    Patent number: 6573259
    Abstract: The present invention relates to novel classes of compounds which are inhibitors of interleukin-1&bgr; converting enzyme (“ICE”). This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting ICE activity and consequently, may be advantageously used as agents against interleukin-1-(“IL-1”), apoptosis-, interferon-&ggr; inducing factor-(IGIF), interferon-&ggr;-(“IFN-&ggr;”) mediated diseases, excess dietary alcohol intake diseases, or viral diseases, including inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, infectious diseases, and degenerative diseases.
    Type: Grant
    Filed: October 23, 2001
    Date of Patent: June 3, 2003
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Julian M. C. Golec, David J. Lauffer, David J. Livingston, Michael D. Mullican, Mark A. Murcko, Philip L. Nyce, Andrea L. C. Robidoux, Marion W. Wannamaker
  • Methods and compositions for treating generalized anxiety disorder
    Patent number: 6358944
    Abstract: The present invention relates to methods and compositions comprising a very low dose of cyclobenzaprine or metabolite thereof for preventing and treating Generalized Anxiety Disorder. The present invention further relates to methods and compositions for treating and preventing symptoms associated with Generalized Anxiety Disorder using a very low dose of cyclobenzaprine.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: March 19, 2002
    Assignee: Vela Pharmaceuticals, Inc.
    Inventors: Seth Lederman, Iredell W. Iglehart, III